FDA
-
-
-
-
-
-
-
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
-
-
-
-
-
-
-
CEL-SCI Corp (CVM) Prices 2.49M Share Offering at $2/sh
-
-
-
-
-
-
-
CEL-SCI Corp (CVM) Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
-
-
-
-
-
-
-
After-hours movers: Masimo sinks on Q2 warning, Pinterest gains on upgrade
-
-
-
-
-
-
-
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
-
-
-
-
-
-
-
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
-
-
-
-
-
-
-
CEL-SCI Corp (CVM) Presents Additional Phase 3 Data
-
251,657 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All